Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending, intranasal INNA-051 doses in healthy adults.

Next Previous
X
Search
Trial Profile

A randomised, double blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending, intranasal INNA-051 doses in healthy adults.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INNA-051 (Primary)
  • Indications COVID 2019 infections; Influenza A virus H3N2 subtype
  • Focus Adverse reactions
  • Sponsors Ena Respiratory

    • Most Recent Events

    • 11 May 2022 According to an Ena Respiratory media release, data from this study will be presented at the 2022 American Thoracic Society International Conference (May 13- 18).
    • 15 Mar 2022 According to an Ena Respiratory media release, complete phase 1 results are expected soon.
    • 23 Feb 2022 According to an Ena Respiratory media release, the company expects to release additional data from the trial this year.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top